PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 25, 2022SHILAP Revista de lepidopterología153 citationsOpen Access

Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis

View Full Paper
RMReda Ben MridNBNajat BouchmaaHAHassan Ainani

Key Points

Key points are not available for this paper at this time.

Abstract

Rheumatoid arthritis (RA) is one of more than 100 types of arthritis. This chronic autoimmune disorder affects the lining of synovial joints in about 0.5% of people and may induce severe joints deformity and disability. RA impacts health life of people from all sexes and ages with more prevalence in elderly and women people. Significant improvement has been noted in the last two decades revealing the mechanisms of the development of RA, the improvement of the early diagnosis and the development of new treatment options. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) remain the most known treatments used against RA. However, not all patients respond well to these drugs and therefore, new solutions are of immense need to improve the disease outcomes. In the present review, we discuss and highlight the recent findings concerning the different classes of RA therapies including the conventional and modern drug therapies, as well as the recent emerging options including the phyto-cannabinoid and cell- and RNA-based therapies. A better understanding of their mechanisms and pathways might help find a specific target against inflammation, cartilage damage, and reduce side effects in arthritis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mrid et al. (2022) studied this question.

synapsesocial.com/papers/69deab147702a00918b0c5dfhttps://doi.org/10.1016/j.biopha.2022.113126
Ask AI
Helpful
Bookmark
Share
View Full Paper